CO5040043A1 - Cristales de peptidos-1 semejantes a glucagon - Google Patents
Cristales de peptidos-1 semejantes a glucagonInfo
- Publication number
- CO5040043A1 CO5040043A1 CO98074132A CO98074132A CO5040043A1 CO 5040043 A1 CO5040043 A1 CO 5040043A1 CO 98074132 A CO98074132 A CO 98074132A CO 98074132 A CO98074132 A CO 98074132A CO 5040043 A1 CO5040043 A1 CO 5040043A1
- Authority
- CO
- Colombia
- Prior art keywords
- glp
- crystals
- analog
- molecule
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un procedimiento para preparar cristales individuales con forma devarilla o semejantes a placas de una molécula relacionada con el péptido-1 semejante a glucagón (GLP), que comprende preparar una solución de cristalización que comprende un GLP, un agente tamponante, un alcohol o un mono- o disacarido y, opcionalmente, sulfato amónico o cinc.Cristales de GLP que tienen una morfología semejante a placas o con forma de varillas planas tetragonales, seleccionados entre el grupo compuesto por un análogo de GLP-1, un derivado de GLP-1, un GLP protegido contra la DPP-IV, un análogo peptídico de GLP-1 o un análogo biosintético de GLP-1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6972897P | 1997-12-16 | 1997-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5040043A1 true CO5040043A1 (es) | 2001-05-29 |
Family
ID=22090845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO98074132A CO5040043A1 (es) | 1997-12-16 | 1998-12-14 | Cristales de peptidos-1 semejantes a glucagon |
Country Status (24)
Country | Link |
---|---|
US (3) | US6380357B2 (es) |
EP (1) | EP0926159A3 (es) |
JP (1) | JP2002508332A (es) |
KR (1) | KR20010033146A (es) |
CN (1) | CN1281369A (es) |
AR (1) | AR019806A1 (es) |
AU (1) | AU1821899A (es) |
BR (1) | BR9813658A (es) |
CA (1) | CA2315243A1 (es) |
CO (1) | CO5040043A1 (es) |
CZ (1) | CZ20002104A3 (es) |
EA (1) | EA200000652A1 (es) |
HR (1) | HRP20000409A2 (es) |
HU (1) | HUP0100046A2 (es) |
ID (1) | ID25534A (es) |
IL (1) | IL136377A0 (es) |
NO (1) | NO20003081L (es) |
NZ (1) | NZ505182A (es) |
PE (1) | PE20000059A1 (es) |
PL (1) | PL341210A1 (es) |
SV (1) | SV1998000147A (es) |
TR (1) | TR200001726T2 (es) |
WO (1) | WO1999030731A1 (es) |
ZA (1) | ZA9811466B (es) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
ES2526707T3 (es) | 1999-06-29 | 2015-01-14 | Mannkind Corporation | Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
WO2001055213A2 (en) * | 2000-01-27 | 2001-08-02 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (glp-1) compounds |
US6844321B2 (en) * | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
WO2001057084A1 (en) * | 2000-01-31 | 2001-08-09 | Novo Nordisk A/S | Crystallisation of a glp-1 analogue |
US20020061838A1 (en) * | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
ATE346093T1 (de) | 2000-06-16 | 2006-12-15 | Lilly Co Eli | Analoge des glucagon ähnlichen peptid-1 |
AU2002228608A1 (en) * | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
CN1501809B (zh) * | 2000-12-13 | 2012-10-10 | 伊莱利利公司 | 应用胰高血糖素样促胰岛肽的长期治疗方案 |
ES2298378T3 (es) * | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
WO2003018516A2 (en) * | 2001-08-23 | 2003-03-06 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | アルブミン融合タンパク質 |
PL209734B1 (pl) * | 2002-02-20 | 2011-10-31 | Emisphere Tech Inc | Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie |
EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
KR20050094832A (ko) * | 2002-12-31 | 2005-09-28 | 알투스 파마슈티컬스 인코포레이티드 | 단백질 결정과 이온성 중합체를 함유하는 복합체 |
WO2004060310A2 (en) | 2002-12-31 | 2004-07-22 | Altus Pharmaceuticals Inc. | Human growth hormone crystals and methods for preparing them |
US20040242568A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2004105781A2 (en) * | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
EP2292254A3 (en) * | 2003-06-03 | 2011-12-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
PL1633391T3 (pl) * | 2003-06-03 | 2012-03-30 | Novo Nordisk As | Stabilizowane farmaceutycznie kompozycje peptydowe |
US7094800B2 (en) * | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) * | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) * | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
DE10335092B3 (de) * | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
MXPA06001601A (es) * | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP5518282B2 (ja) * | 2003-09-01 | 2014-06-11 | ノヴォ ノルディスク アー/エス | 安定なペプチドの製剤 |
US20060247167A1 (en) * | 2003-09-01 | 2006-11-02 | Novo Nordisk A/S | Stable formulations of peptides |
EP1699777B1 (en) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005030751A2 (en) * | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DK3300721T3 (da) * | 2003-11-20 | 2019-05-27 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
AR047776A1 (es) * | 2003-12-16 | 2006-02-22 | Sod Conseils Rech Applic | Composiciones farmaceuticas glp - 1 |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EA013427B1 (ru) * | 2004-03-15 | 2010-04-30 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы дипептидилпептидазы |
US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
CA2575692C (en) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
ES2540853T3 (es) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Sales de dicetopiperazina para la administración de fármacos |
JP4965446B2 (ja) * | 2004-08-31 | 2012-07-04 | ノヴォ ノルディスク アー/エス | ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス(ヒドロキシメチル)アミノメタンの使用 |
RU2413530C9 (ru) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
MX2007009760A (es) | 2005-02-11 | 2007-11-07 | Amylin Pharmaceuticals Inc | Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables. |
US20070004616A1 (en) * | 2005-06-30 | 2007-01-04 | Roland Cherif-Cheikh | GLP-1 pharmaceutical compositions |
EP2441460A1 (en) | 2005-06-30 | 2012-04-18 | Ipsen Pharma | GLP-1 pharmaceutical compositions |
AU2006290205B2 (en) * | 2005-09-14 | 2012-12-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
JP5167133B2 (ja) | 2005-09-14 | 2013-03-21 | マンカインド コーポレイション | 結晶性微粒子表面に対する活性薬剤の親和性の増大に基づく薬物処方の方法 |
PE20070622A1 (es) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidil peptidasa |
CA2622608C (en) * | 2005-09-14 | 2014-08-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
WO2007035629A2 (en) * | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
US9012605B2 (en) * | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US20100029941A1 (en) * | 2006-03-28 | 2010-02-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2007238574B2 (en) * | 2006-04-13 | 2011-08-18 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of hGLP-1, exendin-4 and analogs thereof |
ES2370873T3 (es) * | 2006-09-13 | 2011-12-23 | Takeda Pharmaceutical Company Limited | Utilización del 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo para el tratamiento de la diabetes, el cáncer, los trastornos autoinmunitarios y la infección por el vih. |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
CL2007002634A1 (es) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
MX2010004508A (es) * | 2007-10-24 | 2010-07-02 | Mannkind Corp | Suministro de agentes activos. |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
MX2010004510A (es) * | 2007-10-24 | 2010-07-02 | Mannkind Corp | Metodo para prevenir los efectos nocivos de peptido 1 tipo glucagon (glp-1). |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101672684B1 (ko) | 2008-06-13 | 2016-11-03 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
CA2728523C (en) | 2008-06-20 | 2020-03-10 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
JP2012511586A (ja) | 2008-12-10 | 2012-05-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 医薬組成物 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2853268A1 (en) | 2009-01-08 | 2015-04-01 | Mannkind Corporation | Treatment of hyperglycemia with GLP-1 |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
BRPI1013154B1 (pt) | 2009-06-12 | 2020-04-07 | Mannkind Corp | Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação |
EP2482840A4 (en) * | 2009-08-07 | 2013-06-26 | Mannkind Corp | VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
JP2013525491A (ja) | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 心血管障害を治療または予防し心血管保護を提供する方法 |
AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
WO2012006566A2 (en) * | 2010-07-09 | 2012-01-12 | Amylin Pharmaceuticals, Inc. | Microcrystalline y receptor agonists |
SG10201606220QA (en) | 2011-04-01 | 2016-09-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2852536A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
CN108057154B (zh) | 2012-07-12 | 2021-04-16 | 曼金德公司 | 干粉药物输送系统和方法 |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
CN104107422A (zh) * | 2013-04-16 | 2014-10-22 | 石药集团中奇制药技术(石家庄)有限公司 | 重组胰高血糖素样肽-1受体激动剂的注射用药物组合物 |
AU2014290438B2 (en) | 2013-07-18 | 2019-11-07 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
BR112016016321A2 (pt) | 2014-02-18 | 2017-10-03 | Novo Nordisk As | Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
CN108042794B (zh) * | 2018-01-05 | 2022-01-25 | 北京博康健基因科技有限公司 | 重组促胰岛素分泌素的稳定制剂及其制备方法 |
TW202140063A (zh) | 2020-02-18 | 2021-11-01 | 丹麥商諾佛 儂迪克股份有限公司 | 醫藥配方 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5780599A (en) * | 1990-07-13 | 1998-07-14 | Novo Nordisk A/S | Growth hormone crystals and a process for production of growth hormone crystals |
RU2128663C1 (ru) | 1992-06-15 | 1999-04-10 | Скиос Инк. | Производные полипептида, обладающие инсулинотропной активностью, фармацевтическая композиция, способы усиления действия инсулина, способы лечения диабета |
SE9302278D0 (sv) * | 1992-10-28 | 1993-07-02 | Kabi Pharmacia Ab | Growth hormone |
HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
AU7531094A (en) | 1993-08-24 | 1995-03-21 | Novo Nordisk A/S | Protracted glp-1 |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
EP0658568A1 (en) * | 1993-12-09 | 1995-06-21 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
ATE234625T1 (de) | 1994-12-23 | 2003-04-15 | Novo Nordisk As | Glp-1 zusammensetzungen mit verlängerter wirkdauer |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
CN1271086C (zh) | 1996-08-30 | 2006-08-23 | 诺沃挪第克公司 | Glp-1衍生物 |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
ES2290799T3 (es) | 1996-11-12 | 2008-02-16 | Novo Nordisk A/S | Uso de peptidos glp-1. |
CA2283834A1 (en) | 1997-03-31 | 1998-10-08 | James Arthur Hoffmann | Glucagon-like peptide-1 analogs |
US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
-
1998
- 1998-12-11 US US09/209,799 patent/US6380357B2/en not_active Expired - Lifetime
- 1998-12-14 NZ NZ505182A patent/NZ505182A/en unknown
- 1998-12-14 JP JP2000538710A patent/JP2002508332A/ja not_active Withdrawn
- 1998-12-14 WO PCT/US1998/026480 patent/WO1999030731A1/en not_active Application Discontinuation
- 1998-12-14 CZ CZ20002104A patent/CZ20002104A3/cs unknown
- 1998-12-14 CN CN98812093A patent/CN1281369A/zh active Pending
- 1998-12-14 CO CO98074132A patent/CO5040043A1/es unknown
- 1998-12-14 CA CA002315243A patent/CA2315243A1/en not_active Abandoned
- 1998-12-14 KR KR1020007006521A patent/KR20010033146A/ko not_active Application Discontinuation
- 1998-12-14 EP EP98310245A patent/EP0926159A3/en not_active Withdrawn
- 1998-12-14 ID IDW20001139A patent/ID25534A/id unknown
- 1998-12-14 PL PL98341210A patent/PL341210A1/xx not_active Application Discontinuation
- 1998-12-14 ZA ZA9811466A patent/ZA9811466B/xx unknown
- 1998-12-14 IL IL13637798A patent/IL136377A0/xx unknown
- 1998-12-14 HU HU0100046A patent/HUP0100046A2/hu unknown
- 1998-12-14 TR TR2000/01726T patent/TR200001726T2/xx unknown
- 1998-12-14 EA EA200000652A patent/EA200000652A1/ru unknown
- 1998-12-14 AU AU18218/99A patent/AU1821899A/en not_active Abandoned
- 1998-12-14 BR BR9813658-5A patent/BR9813658A/pt not_active IP Right Cessation
- 1998-12-14 SV SV1998000147A patent/SV1998000147A/es unknown
- 1998-12-15 AR ARP980106356A patent/AR019806A1/es unknown
- 1998-12-15 PE PE1998001225A patent/PE20000059A1/es not_active Application Discontinuation
-
2000
- 2000-06-15 NO NO20003081A patent/NO20003081L/no not_active Application Discontinuation
- 2000-06-16 HR HR20000409A patent/HRP20000409A2/hr not_active Application Discontinuation
-
2001
- 2001-11-30 US US09/997,792 patent/US6555521B2/en not_active Ceased
-
2005
- 2005-04-29 US US11/119,500 patent/USRE41133E1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6380357B2 (en) | 2002-04-30 |
EP0926159A2 (en) | 1999-06-30 |
KR20010033146A (ko) | 2001-04-25 |
AU1821899A (en) | 1999-07-05 |
US20030045464A1 (en) | 2003-03-06 |
PE20000059A1 (es) | 2000-02-09 |
USRE41133E1 (en) | 2010-02-16 |
US20010014666A1 (en) | 2001-08-16 |
CZ20002104A3 (cs) | 2001-08-15 |
HRP20000409A2 (en) | 2000-10-31 |
CN1281369A (zh) | 2001-01-24 |
TR200001726T2 (tr) | 2000-10-23 |
AR019806A1 (es) | 2002-03-20 |
BR9813658A (pt) | 2000-10-10 |
EA200000652A1 (ru) | 2000-12-25 |
ID25534A (id) | 2000-10-12 |
ZA9811466B (en) | 2000-06-14 |
CA2315243A1 (en) | 1999-06-24 |
HUP0100046A2 (hu) | 2001-05-28 |
NO20003081D0 (no) | 2000-06-15 |
WO1999030731A1 (en) | 1999-06-24 |
US6555521B2 (en) | 2003-04-29 |
EP0926159A3 (en) | 2003-11-26 |
JP2002508332A (ja) | 2002-03-19 |
PL341210A1 (en) | 2001-03-26 |
NZ505182A (en) | 2002-05-31 |
SV1998000147A (es) | 1999-08-18 |
NO20003081L (no) | 2000-08-08 |
IL136377A0 (en) | 2001-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5040043A1 (es) | Cristales de peptidos-1 semejantes a glucagon | |
WO2000066142A3 (en) | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain | |
BR9401185A (pt) | Processo para o tratamento de diabetes mellitus e composição de matéria | |
WO2003011892A3 (en) | Glp-1 exendin-4 peptide analogs and uses thereof | |
AR018068A1 (es) | Una composicion de veneno estomacal para moluscos, una composicion molusquicida ingerible y un metodo para exterminar las plagas de moluscos indeseables | |
AR017819A1 (es) | Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos | |
PE20001031A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
AR018526A1 (es) | COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED | |
GB9108652D0 (en) | Immunoreactive compounds | |
NZ514610A (en) | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue | |
CA2120626A1 (en) | Method for enhancing gut absorption | |
WO2004019758A3 (en) | Methods of treating idiopathic pulmonary fibrosis | |
AU3473999A (en) | Injectable igf-formulations containing succinate as buffering agent | |
AR019724A2 (es) | Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas | |
ES2031629T3 (es) | Banda metalica en la forma de lamina. | |
Lavery | Local Group Dwarf Galaxy in Tucana | |
Wyon et al. | Crystal growth of LaMgAI 11 O 19: Nd | |
IL140341A0 (en) | Seeding crystals for preparation of peptides or proteins | |
Eckstein et al. | Crystal growth of lead (II) iodide from the melt | |
Zhang et al. | Formation of target field-reversed configuration plasma for magnetized target fusion in frx-l | |
Varleva et al. | The growth of silver whiskers by reduction of silver halogenides | |
Hayashi | Application of radiation technology in biomedical materials; Fundamentals and applied | |
ECSP982593A (es) | Nuevo metodo de tratamiento vi | |
Mata et al. | COS 12-3: The impact of propagule pressure on invasion success | |
Mycielski et al. | ZnTe Bulk Crystals |